WO2005000235A3 - NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME - Google Patents

NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME Download PDF

Info

Publication number
WO2005000235A3
WO2005000235A3 PCT/US2004/018962 US2004018962W WO2005000235A3 WO 2005000235 A3 WO2005000235 A3 WO 2005000235A3 US 2004018962 W US2004018962 W US 2004018962W WO 2005000235 A3 WO2005000235 A3 WO 2005000235A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
compositions
disclosed
methods
signal peptide
Prior art date
Application number
PCT/US2004/018962
Other languages
French (fr)
Other versions
WO2005000235A2 (en
Inventor
David B Weiner
Michele Kutzler
Andrew K Choo
Joo-Sung Yang
Jean D Boyer
Original Assignee
Univ Pennsylvania
David B Weiner
Michele Kutzler
Andrew K Choo
Joo-Sung Yang
Jean D Boyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020117023822A priority Critical patent/KR101225473B1/en
Priority to BRPI0411363-2A priority patent/BRPI0411363A/en
Priority to AU2004251070A priority patent/AU2004251070B2/en
Priority to MXPA05013526A priority patent/MXPA05013526A/en
Application filed by Univ Pennsylvania, David B Weiner, Michele Kutzler, Andrew K Choo, Joo-Sung Yang, Jean D Boyer filed Critical Univ Pennsylvania
Priority to US10/560,650 priority patent/US8173786B2/en
Priority to JP2006533791A priority patent/JP2007516696A/en
Priority to NZ544077A priority patent/NZ544077A/en
Priority to EP04776577.1A priority patent/EP1638987B1/en
Priority to KR1020057023994A priority patent/KR101269548B1/en
Priority to CN2004800228915A priority patent/CN1832956B/en
Priority to CA2529145A priority patent/CA2529145C/en
Publication of WO2005000235A2 publication Critical patent/WO2005000235A2/en
Publication of WO2005000235A3 publication Critical patent/WO2005000235A3/en
Priority to IL172496A priority patent/IL172496A/en
Priority to US13/466,015 priority patent/US20120276142A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions.
PCT/US2004/018962 2003-06-13 2004-06-14 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME WO2005000235A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2006533791A JP2007516696A (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding IgE signal peptide and / or IL-15, compositions comprising them and methods of use thereof
AU2004251070A AU2004251070B2 (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
MXPA05013526A MXPA05013526A (en) 2003-06-13 2004-06-14 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME.
EP04776577.1A EP1638987B1 (en) 2003-06-13 2004-06-14 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
US10/560,650 US8173786B2 (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
BRPI0411363-2A BRPI0411363A (en) 2003-06-13 2004-06-14 nucleic acid sequences encoding and compositions comprising signal peptide ige and / or il-15 and processes for use thereof
NZ544077A NZ544077A (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR1020117023822A KR101225473B1 (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR1020057023994A KR101269548B1 (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CN2004800228915A CN1832956B (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same
CA2529145A CA2529145C (en) 2003-06-13 2004-06-14 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same
IL172496A IL172496A (en) 2003-06-13 2005-12-11 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
US13/466,015 US20120276142A1 (en) 2003-06-13 2012-05-07 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47820503P 2003-06-13 2003-06-13
US47821003P 2003-06-13 2003-06-13
US60/478,210 2003-06-13
US60/478,205 2003-06-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/466,015 Division US20120276142A1 (en) 2003-06-13 2012-05-07 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same

Publications (2)

Publication Number Publication Date
WO2005000235A2 WO2005000235A2 (en) 2005-01-06
WO2005000235A3 true WO2005000235A3 (en) 2005-06-16

Family

ID=33555491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018962 WO2005000235A2 (en) 2003-06-13 2004-06-14 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME

Country Status (12)

Country Link
US (2) US8173786B2 (en)
EP (2) EP2292634A3 (en)
JP (2) JP2007516696A (en)
KR (2) KR101225473B1 (en)
CN (1) CN1832956B (en)
AU (2) AU2004251070B2 (en)
BR (1) BRPI0411363A (en)
CA (1) CA2529145C (en)
IL (1) IL172496A (en)
MX (1) MXPA05013526A (en)
NZ (2) NZ570709A (en)
WO (1) WO2005000235A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU2007208452B2 (en) * 2006-01-13 2012-07-05 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized IL-15 and methods for using the same
KR101999376B1 (en) 2006-07-28 2019-07-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Improved vaccines and methods for using the same
US10426827B1 (en) * 2006-11-06 2019-10-01 Microvax, Llc Dengue hemorrhagic fever virus vaccine
AU2009210624A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US10071154B2 (en) * 2008-04-04 2018-09-11 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2009124312A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CA2771334A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
WO2011097640A1 (en) * 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
PL2672992T3 (en) 2011-02-11 2020-11-02 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
JP2015514132A (en) * 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human respiratory syncytial virus consensus antigens, nucleic acid constructs, vaccines made therefrom, and methods of use thereof
KR20240010758A (en) * 2012-04-12 2024-01-24 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
WO2014186469A2 (en) * 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
KR102586707B1 (en) * 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines having an antigen and interleukin-21 as an adjuvant
AU2016341311B2 (en) * 2015-10-22 2023-11-16 Modernatx, Inc. Respiratory syncytial virus vaccine
EA201892124A1 (en) 2016-12-02 2019-04-30 Дэвид Б. Уэйнер DNA STRUCTURES OF ANTIBODIES AND METHODS OF THEIR APPLICATION
CU24546B1 (en) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia VACCINAL COMPOSITION INCLUDING A HUMAN INTERLEUKIN-15 MUTANT
JP7288401B2 (en) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド Modulation of polypeptide expression via a novel gene switch expression system
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
US20220133885A1 (en) * 2020-11-02 2022-05-05 Drexel University Compositions and methods employing adenosine deaminase-1 (ada-1) as an adjuvant
EP4329786A1 (en) * 2021-04-30 2024-03-06 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123099A1 (en) * 2000-10-04 2002-09-05 Weiner David B. Highly expressible genes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
CH682669A5 (en) 1989-03-08 1993-10-29 Health Research Inc recombinant virus engineered to express a gene product in a host, corresponding methods and vaccine.
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
DE69016956T2 (en) 1989-12-04 1995-07-20 Akzo Nobel Nv Recombinant turkey herpes virus and derived live vaccine vector.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
JP3701966B2 (en) 1993-01-26 2005-10-05 ウェイナー，デービッド・ビー Compositions and methods for delivery of genetic material
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (en) 1994-11-02 1996-06-03 Meyn Maschf Device for processing poultry suspended from its legs.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
ES2305024T3 (en) 1995-08-01 2008-11-01 F. Hoffmann-La Roche Ag RECEPTORS FOR INTERLEUQUINA-12 HUMANA.
KR20050053796A (en) * 1996-10-23 2005-06-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Immunotherapy and improved vaccines
WO1999016466A2 (en) * 1997-09-29 1999-04-08 Beth Israel Deaconess Medical Center Vaccine compositions and methods of enhancing vaccine efficacy
JP2001526241A (en) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Methods for reducing susceptibility to HIV infection
JP2002507392A (en) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Optimization of immunomodulatory properties of gene vaccines
US7560105B1 (en) 1999-10-04 2009-07-14 Leids Universitair Medisch Centrum Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
EP2269629A3 (en) 2000-05-11 2013-09-11 Baylor Research Institute Compositions and methods for producing antigen-presenting cells
RS51829B (en) 2001-08-23 2012-02-29 Genmab A/S. Human antibodies specific for interleukin 15 (il-15)
AU2003243663A1 (en) * 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR20140137679A (en) 2013-05-23 2014-12-03 삼성전자주식회사 Socket for card

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123099A1 (en) * 2000-10-04 2002-09-05 Weiner David B. Highly expressible genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANETHER ET AL: "Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia", BLOOD, vol. 99, pages 722 - 723, XP002987799 *
RUCKERT ET AL: "II-15-IgG2b fusion protein accelerates and enhances a TH2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both", EUR. J. IMMUNOL., vol. 28, December 1998 (1998-12-01), pages 3312 - 3320, XP002230807 *
WIERDA ET AL: "CD40-ligand (CD145) gene therapy for chronic lymphocytic leukemia", BLOOD, vol. 96, November 2000 (2000-11-01), pages 2917 - 2924, XP002987798 *

Also Published As

Publication number Publication date
NZ570709A (en) 2010-04-30
EP1638987A4 (en) 2007-12-26
KR20060030041A (en) 2006-04-07
MXPA05013526A (en) 2006-03-09
CN1832956B (en) 2013-11-20
JP2007516696A (en) 2007-06-28
WO2005000235A2 (en) 2005-01-06
EP1638987A2 (en) 2006-03-29
IL172496A0 (en) 2006-04-10
AU2004251070A1 (en) 2005-01-06
KR101269548B1 (en) 2013-06-21
AU2012202867B2 (en) 2015-01-29
JP2012110345A (en) 2012-06-14
CN1832956A (en) 2006-09-13
AU2004251070B2 (en) 2012-02-23
US8173786B2 (en) 2012-05-08
KR101225473B1 (en) 2013-01-24
US20070041941A1 (en) 2007-02-22
KR20110129945A (en) 2011-12-02
EP1638987B1 (en) 2014-11-19
IL172496A (en) 2013-02-28
US20120276142A1 (en) 2012-11-01
BRPI0411363A (en) 2006-07-25
NZ544077A (en) 2009-01-31
AU2012202867A1 (en) 2012-06-07
CA2529145A1 (en) 2005-01-06
CA2529145C (en) 2017-07-11
EP2292634A3 (en) 2012-08-08
EP2292634A2 (en) 2011-03-09
JP5623444B2 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
WO2005000235A3 (en) NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
MX362028B (en) Extended recombinant polypeptides and compositions comprising same.
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
MX2010005783A (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
WO2002014358A3 (en) Novel secreted proteins and their uses
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX354555B (en) Growth hormone polypeptides and methods of making and using same.
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
WO2003066820A3 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2001087978A3 (en) Human abc transporter and its use
WO2002070665A8 (en) Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2002032939A3 (en) Secreted proteins and their uses
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2002048361A3 (en) Novel secreted proteins and their uses
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
PL1664097T3 (en) Piroplasmid vaccine
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2004024769A3 (en) Ostertagia vaccine
WO2004013281A3 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022891.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172496

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 544077

Country of ref document: NZ

Ref document number: 2529145

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013526

Country of ref document: MX

Ref document number: 1020057023994

Country of ref document: KR

Ref document number: 12005502247

Country of ref document: PH

Ref document number: 2006533791

Country of ref document: JP

Ref document number: 2581/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004251070

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 05129156

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2004251070

Country of ref document: AU

Date of ref document: 20040614

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004776577

Country of ref document: EP

Ref document number: 200600336

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004251070

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004776577

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057023994

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007041941

Country of ref document: US

Ref document number: 10560650

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0411363

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10560650

Country of ref document: US